Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Mar 31.

Published in final edited form as: Gynecol Oncol. 2009 Jul 12;115(1):81–85. doi: 10.1016/j.ygyno.2009.06.021

Table 3.

Association of CA-125 levels during treatment with progress-free survival (PFS) and overall survival (OS).

	PFS			OS
	HR	95% C.I.	P value	HR	95% C.I.	P value
Baseline CA125
Log₂(CA125)	1.10	1.02–1.18	0.009	1.09	1.01–1.17	0.032
≥35 versus < 35 U/ml	0.99	0.65–1.52	0.961	1.16	0.71–1.90	0.565
Pre-2nd cycle
Log₂(CA125)	1.24	1.15–1.34	<0.001	1.26	1.16–1.37	<0.001
≥35 versus < 35 U/ml	1.98	1.47–2.66	<0.001	2.88	2.01–4.16	<0.001
Pre-4th cycle
Log₂(CA125)	1.39	1.21–1.59	<0.001	1.46	1.26–1.68	<0.001
≥35 versus < 35 U/ml	1.80	1.27–2.56	0.001	1.94	1.31–2.85	<0.001
Pre-6th cycle
Log₂(CA125)	1.35	1.13–1.61	0.001	1.61	1.32–1.96	<0.001
≥35 versus < 35 U/ml	2.45	1.52–3.95	<0.003	2.78	1.66–4.65	<0.001

Hazard ratio (HR) estimated from Cox model adjusted for tumor residual, histology and type of chemotherapy.